Single-center 'real life experience' with pembrolizumab (PEMBRO) in advanced melanoma patients and analysis of baseline factors that correlate with outcome

Y. Jansen; M. Schreuer; B. Neyns

Single-center 'real life experience' with pembrolizumab (PEMBRO) in advanced melanoma patients and analysis of baseline factors that correlate with outcome

Y. Jansen, M. Schreuer, B. Neyns

Research output: Contribution to journal › Meeting abstract (Journal)

Original language	English
Article number	P045
Pages (from-to)	E33-E34
Number of pages	2
Journal	Melanoma Research
Volume	26
Publication status	Published - Aug 2016
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States Duration: 2 Jun 2016 → 7 Jun 2016

Handle.net

Persistent link

Cite this

@article{4069117c1aaf4af18c452dc1842e7586,

title = "Single-center 'real life experience' with pembrolizumab (PEMBRO) in advanced melanoma patients and analysis of baseline factors that correlate with outcome",

author = "Y. Jansen and M. Schreuer and B. Neyns",

year = "2016",

month = aug,

language = "English",

volume = "26",

pages = "E33--E34",

journal = "Melanoma Research",

issn = "0960-8931",

publisher = "Lippincott Williams and Wilkins",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 02-06-2016 Through 07-06-2016",

}

TY - JOUR

T1 - Single-center 'real life experience' with pembrolizumab (PEMBRO) in advanced melanoma patients and analysis of baseline factors that correlate with outcome

AU - Jansen, Y.

AU - Schreuer, M.

AU - Neyns, B.

PY - 2016/8

Y1 - 2016/8

M3 - Meeting abstract (Journal)

SN - 0960-8931

VL - 26

SP - E33-E34

JO - Melanoma Research

JF - Melanoma Research

M1 - P045

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 2 June 2016 through 7 June 2016

ER -